Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia

CONCLUSION: The pharmacokinetics of PEGasparaginase in infants diagnosed under one year of age with ALL is comparable to that of older children (1-18 years). We recommend a PEGasparaginase dosing at 1,500 IU/m2 for infants without dose adaptations according to age, and implementing therapeutic drug monitoring as standard practice.PMID:38538970 | DOI:10.1007/s11095-024-03693-3

Source: Cell Research - March 28, 2024 Category: Cytology Authors: Leiah J Brigitha Veerle Mondelaers Yiwei Liu Birgitte K Albertsen Beata Zalewska-Szewczyk Carmelo Rizzari Rishi S Kotecha Rob Pieters Alwin D R Huitema Inge M van der Sluis Source Type: research